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Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved
in the European Union and the United States of America for the prevention of thrombosis after major orthopedic
surgery. It has also been approved by the American Food and Drug Administration and the European Medicines
Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect
without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical
evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral
anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage
renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
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Introduction
Dabigatran is an emerging drug which acts as a direct
and reversible thrombin inhibitor. Due to its predictable
pharmacokinetic profile, it is expected to replace, at
least in part, vitamin K inhibitors in the prevention of
venous thromboembolism and atrial fibrillation. In parti-
cular, patients on dabigatran therapy do not need peri-
odic International Normalized Ratio (INR) controls.
Studies included in the present review article have been
selected from PubMed. For clinical trials, the inclusion
criterion was Randomized Clinical Trials. For the search
of ongoing trials, the National Institute of Health Regis-
try was consulted http://www.clinicaltrials.gov.
1. Pharmacology of dabigatran
2.1. Mechanism of action
The chemical structure of dabigatran is shown in Figure
1. It is a direct inhibitor of thrombin activity (factor II
of the human coagulation system). Dabigatran is a pepti-
domimetic inhibitor of the thrombin. It imitates part of
the molecular structure of the fibrinogen, especially in
the zone where thrombin and fibrinogen interact and
make possible the conversion to fibrin. Dabigatran
possesses a benzylimidazolic nucleus, which is bound to
a branch of amidinofenylalanine as a false arginine. The
dabigatran molecule also possesses a carboxylic residue
which increases the hydrophilic capacity of the drug.
Thus, dabigatran inhibits the key role of thrombin in
human hemostasis. Thrombin plays a central role in the
regulation of the coagulation system by activating fac-
tors V, XI and fibrinogen itself (factor I).
Dabigatran is a reversible thrombin inhibitor with an
inhibition constant of (IC50) of 4.5 ± 0.2 nM [1,2]. Dabi-
gatran inhibits the generation of thrombin by platelet-
rich plasma in human volunteers [1]. It inhibits platelet
aggregation by thrombin with an IC50 of 10 mM [1].
However, dabigatran is unable to inhibit the platelet
aggregation induced by arachidonic acid, collagen or
ADP.
2.2. Pharmacokinetics
Pharmacokinetics of dabigatran have been assessed in sev-
eral studies using repeated doses on human volunteers.
Dabigatran is given orally as a prodrug termed dabigatran
etexilate. In the peripheral blood, it is activated [3], having
a maximum peak time (Tmax) from 0.5 to 1 h, and a maxi-
mum concentration (Cmax) of 146 ng/ml, for the dosis of
1 5 0m gt w i c ead a y[ 4 ] .I t sa r e au n d e rc u r v e( A U C )i s
1080 ng*h/ml [3]. Dabigatran is bound to the plasmatic
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esterases instead of p450 cytochrome [4].
Distribution volume of dabigatran is 60-70 l, its half-
life is 12-24 h and its oral biodisposability is 7% [1,3].
Dabigatran is eliminated in urine and stools. It is mainly
excreted in a non-metabolized form by urine by 80%,
and conjugated with glucoronic acid and eliminated in
stools by 20%. In patients with end-stage renal disease,
Cmax of the doses of 150 mg every 12 h can be increased
from 100 to 250 ng/ml [5]. Thus, patients with end-
stage renal disease were excluded from the clinical trials.
However, the current label of the drug in the European
Union allows dabigatran for patients with a moderate
renal disease (CLCR 30-50 ml/min), based on pharmaco-
kinetics. In particular, in elderly patients (> 75 years), or
those with moderate renal impairment (CLCR 30-50 ml/
min) only the dose of 150 mg is recommended, starting
with a half dose [6].
Dabigatran pharmacokinetics is very relevant for its
clinical dosing, especially in the post-surgical setting.
The BISTRO I study (289 patients) performed a dose-
escalating design for the prophylaxis of thrombosis in
major orthopedic surgery (hip replacement). In this
phase I trial, the first dose was given 4-8 h after surgery.
Doses were 12.5, 25, 50, 100, 150, 200 or 300 mg twice
a day, and 100 or 300 mg once a day [4]. The primary
efficacy endpoint was venous thromboembolism (mea-
sured by venography), and the primary safety endpoint
was the rate of major bleeding events. The overall rate
of thromboembolism was 12.4%, and it decreased from
20.8% at 12.5 mg twice a day to 0% at 300 mg twice a
day. No major hemorrhagic events were registered.
H o w e v e r ,2o ft h e2 0p a t i e n t so n3 0 0m gt w i c ead a y
developed bleeding from multiple sites. Thus, the opti-
mal therapeutical window was established above 12.5
mg and below 300 mg twice a day [4].
Dabigatran is able to increase the prothrombin time
(PT and the ratio INR), activated partial thromboplastin
time (APTT), the thrombin time (TT) and the ecarin
time (ECT). In clinical trials, APTT was correlated with
the blood concentration of the drug. Moreover, there
was a close relationship between APTT and the primary
efficacy and safety outcomes. Therefore, the higher
increase of APTT was associated with decreased throm-
bosis, increased bleeding, and higher blood concentra-
tion of the drug in the two phase II trials BISTRO II
(for the prevention of thrombosis in total hip or knee
replacement) [7], and PETRO (for the prevention of
thromboembolic stroke in chronic atrial fibrillation) [8].
However, the prolongation of the ECT is directly and
linearly related to the plasmatic levels of dabigatran.
Thus, ECT may be considered as the future test of
choice for the clinical monitoring of the effect of dabiga-
tran when needed [5].
2.3. Drug interactions
Dabigatran is not metabolized by the p450 cytochrome
system. However, the efflux transporter P-gp is involved
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can be theoretically modulated by P-gp inhibitors (vera-
pamil, quinidine, clarithromycin, ketoconazole and
amiodarone), or P-gp inducers (rifampicin). In the prac-
tice, the maximum increase in AUC (up to 150%) has
been observed with ketoconazole. Quinidine, amiodar-
one and verapamil can increase bioavailability of dabiga-
tran up to 50% [9]. The current European Medicines
Agency label of the drug recommends dose reduction in
patients on amiodarone treatment [6].
Antiplatelet drugs may cause bleeding. In atrial fibril-
lation trials, some patients were treated with dabigatran
and aspirin. In the phase II PETRO study, major bleed-
ing events were limited to the group of 300 mg dabiga-
tran twice a day plus aspirin (4 of 64), compared to the
group of 300 mg dabigatran twice a day alone (0 of 105,
p < 0.02) [8]. However, in the phase III RE-LY trial,
aspirin at doses lower than 100 mg was allowed and no
significant rate of hemorrhage was observed in the
patients who were treated with dabigatran (110 or 150
mg twice a day), plus aspirin [10]. Nevertheless, in this
same trial dabigatran 150 mg had significantly more gas-
trointestinal bleeding as compared to coumadin (182 v/s
120 patients, p < 0.001) [10].
2.4. Secondary effects
Given that hepatotoxicity was the reason for the clinical
withdrawal of ximelagatran [11], the previous direct
thrombin inhibitor, the hepatic biochemical function has
been intensively studied in the clinical trials of
dabigatran.
To date, not a single clinical trial has demonstrated a
significant increase of transaminase enzymes. In dose-
escalating trials, a dose-dependent increase of transami-
nase enzymes is equally not observed [4,5,10,12].
A common adverse effect of dabigatran is dyspepsia.
This may be due to the pills being embedded in tartaric
acid to facilitate its absorption [9].
Dabigatran increased urinary excretion of 11-dehydro-
thromboxane B2 (DTB2) up to 20% in the phase II
PETRO study [8]. This could theoretically increase the
thrombotic risk. Of note, this DTB2 increase was not
observed when dabigatran was given with aspirin in this
clinical trial [8]. Ximelagatran, the previous thrombin
inhibitor, decreased cardiac events when given in addi-
tion to aspirin [11].
3. Clinical evidence
3.1. Dabigatran for total hip or knee replacement surgery
Prophylaxis of thrombosis in hip and knee replacement
surgery is the first indication approved for dabigatran,
by the European Medicines Agency (EMA) and the Uni-
ted States Food and Drug Administration (FDA). The
BISTRO I study, which has been commented on above,
was a multicentric and sequential phase I trial where
dabigatran was used in an escalating-dose schedule on
289 patients [4]. Results showed a reasonable therapeu-
tic window for the drug, with low risks of thrombosis
and hemorrhage, in patients over 12.5 mg once a day,
and below 300 mg twice a day [4]. The BISTRO II was
a double-blind phase II trial to compare the efficacy and
safety of dabigatran versus daily enoxaparin (40 mg a
day) on 1973 patients [7]. The primary efficacy outcome
was the rate of venous thrombosis (measured by veno-
gram), whereas the primary safety endpoint was the risk
of major bleeding. Dabigatran showed a clear dose-
dependent antithrombotic effect (p < 0.0001). Compared
with enoxaparin 40 mg once a day, dabigatran achieved
a lower rate of thrombotic events, for the doses of 150
mg twice a day (OR 0.65, p = 0.04), 300 mg once a day
(OR 0.61, p = 0.02), and 225 mg twice a day (OR 0.47, p
= 0.0007). Compared to the enoxaparin group, dabiga-
tran showed a lower hemorrhagic risk for the dose of 50
mg twice a day (0.3% v 2%, p = 0.047), though the dif-
ference was not significant for the doses of 150 mg
twice a day (4.1%, p = 0.1), 225 mg twice a day (3.8%, p
= 0.15), and 300 mg once a day (4.7%, p = 0.051) [7].
The RE-MODEL was a randomized, prospective, dou-
ble-blind, non-inferiority phase III trial which was
designed to compare dabigatran and enoxaparin 40 mg
once a day on 2076 patients who underwent knee repla-
cement surgery [12]. Dabigatran was used at a dose of
150 mg or 220 mg once a day. The first dose was one-
half of subsequent doses and it was administered 1-4 h
after completion of the surgery. Compared to enoxa-
parin, dabigatran did not show a different profile in
terms of prevention of thrombosis and hemorrhage. The
primary efficacy outcome was a composite endpoint of
venographic thrombosis and/or clinical thrombosis and
mortality. This efficacy outcome had a rate of 37.7% in
the enoxaparin group vs. 36.4% in the dabigatran 220
mg/24 h group (95% CI -7.3 to 4.6), and 40.5% in the
150 mg/24 h group (95% to CI -3.1 to 8.7). The rate of
major hemorrhage was 1.3% in the enoxaparin group,
1.5% in dabigatran 220 mg (p = 0.82) and 1.3% in dabi-
gatran 150 mg (p = 1.0) [12].
Similar conclusions were achieved by the RE-
NOVATE trial for hip replacement [13]. It was a pro-
spective, phase III, randomized clinical trial on 3494
patients. The primary efficacy endpoint was the compo-
site of total thromboembolic events and all-cause mor-
t a l i t y ,w h i l et h es a f e t yo u t c o m ew a st h er a t eo fm a j o r
hemorrhage. Enoxaparin 40 mg once a day had a rate of
6.7% of thrombosis/mortality. Dabigatran showed a non-
inferior efficacy profile for both doses (6% in 220 mg
once a day, p < 0.0001 for non-inferiority, and 8.6% for
150 mg one a day, p < 0.0001 for non-inferiority). The
rate of major bleeding was also not significant for
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In particular, the enoxaparin group had a hemorrhagic
risk of 1.6%, while dabigatran 220 mg had a 1% (p =
0.44), and dabigatran 150 mg had 1.3% (p = 0.60) [13].
The double-blind RE-MOBILIZE trial, however,
reached different results [14]. It was a prospective, dou-
ble-blind, randomized phase III trial for the prevention
of thrombosis after knee arthroplasty on 2596 patients.
In this study, enoxaparin was used at 30 mg twice a day
(the American standard) vs dabigatran at 220 or 150 mg
once a day [14]. The primary efficacy and safety out-
comes were the same as described for RE-MODEL and
RE-NOVATE. Dabigatran failed to show a non-inferior
efficacy compared to enoxaparin 30 mg twice a day. The
risk difference was 5.8% for dabigatran 220 mg (95% CI,
0.8-10.8, p = 0.0234) and 8.4% for dabigatran 150 mg
(95% CI, 3.4-13.3, p = 0.0009). The rate of bleeding
events, however, was not statistically significant among
groups [14].
A meta-analysis performed a pooled analysis of these
three trials: RE-MODEL, RE-NOVATE and RE-MOBI-
LIZE (8135 patients) [15]. The pooled rate of thrombo-
sis or thrombosis-related mortality was 3.3% in the
enoxaparin group vs 3% of dabigatran 220 mg group (p
= 0.20), and 3.8% of the dabigatran 150 mg group (p =
0.91). The rate of major bleeding was 1.4% in the enoxa-
parin group vs. 1.4% in dabigatran 220 mg (p = 0.61)
and 1.1% in dabigatran 150 mg (p = 0.16). Subgroup
analyses suggested that bleeding risk appeared to be
higher in patients with moderate renal impairment
(ClCR 30-50 ml/min) and in patients older than 75
years. There was no evidence of statistical heterogeneity
among the three trials [15].
Thus, the current clinical evidence strongly supports
the indication of dabigatran for the prevention of
thrombosis in patients who underwent hip or knee
replacement surgery, with a reasonable efficacy and
safety profile. Dabigatran has been approved for this
indication in the European Union for the dose of 220
mg once a day, with a starting dose of 110 mg 1-4 h
after surgery. For patients with moderate renal impair-
ment, older than 75 years, or on amiodarone treatment,
the dose of 75 mg twice a day is recommended (with a
starting dose of 75 mg 1-4 h after surgery) [6].
3.2. Other situations of deep venous thrombosis/
pulmonary embolism
The RE-COVER study was a randomized, double-blind
and non-inferiority phase III trial where dabigatran and
warfarin were evaluated for the treatment of deep
venous thrombosis on 2564 patients [16]. Follow-up was
6 months and low molecular weight heparin was used
prior to oral anticoagulation in both groups. Dabigatran
was administered at a constant dose of 150 mg twice a
day, whereas warfarin was used at a dose to achieve an
INR between 2 and 3. The efficacy endpoint was a com-
posite of symptomatic venous thromboembolism or
related death. It had a rate of 2.4% in the dabigatran
group and 2.1% in the warfarin group (hazard ratio 1.10,
95% CI, 0.65-1.84). Dabigatran proved non-inferior with
regards to the prevention of recurrent or fatal venous
thromboembolism (p < 0.001 for non-inferiority). Of
note, the rate major or clinical relevant non-major
bleeding events was 5.6% in the dabigatran group vs.
8.8% in the warfarin group (hazard ratio 0.63%, 95% CI,
0.47-0.84, p = 0.0002 [16]. Therefore, dabigatran may
suppose a future clinical choice for the treatment of
deep venous thrombosis/pulmonary embolism.
3.2. Dabigatran for chronic atrial fibrillation
The PETRO randomized phase II trial compared the
effect of vitamin K antagonists versus dabigatran at
doses at 50, 150 or 300 mg twice a day, with or without
aspirin at 82 or 325 mg, on 502 patients [8]. The pri-
mary outcome was the rate of bleeding events. Major
bleeding events were limited to the group treated with
300 mg dabigatran twice a day plus aspirin compared to
300 mg dabigatran twice a day alone (p < 0.02). Total
bleeding events were lower in the 50 mg group (7%),
compared with the 300 mg group (23%, p = 0.0002) and
the 150 group (18%, p = 0.01). The group of 50 mg had
a rate of 2%of thromboembolic events. Therefore, an
optimal dose from 150 mg twice a day to lower than
300 mg twice a day was selected for further studies [8].
The randomized, double-blind RE-LY phase III trial
assessed the efficacy and safety profile of dabigatran
(110 or 150 mg twice a day) on 18113 patients, com-
pared to warfarin. The median duration of the follow-up
period was 2 years. The primary efficacy outcome was
stroke or systemic embolism. The primary safety out-
come was a major hemorrhage [10]. Stroke or systemic
embolism had a rate of 1.53% per year in the group of
dabigatran 110 mg twice a day, and 1.11% per year in
the group of dabigatran 150 mg twice a day. Both doses
of dabigatran were non-inferior to warfarin (p < 0.001).
For the prevention of thrombotic events, the dose of
150 mg was superior to warfarin (relative risk 0.66, 95%
CI, 0.53-0.82, p < 0.001), whereas the dose of 110 mg
was not (relative risk 0.91, 95% CI, 0.74-1.11, p = 0.34).
In contrast, the rate of major bleeding was 3.36% per
year in the warfarin group, while it was 3.11% per year
in the 150 mg dabigatran group (relative risk of 0.93, CI
95%, 0.81-1.07, p = 0.31) and 2.71% per year in the 110
mg dabigatran group (relative risk of 0.8, CI 95%, 0.69-
0.93, p = 0.003) [10].
The FDA approved dabigatran for the prevention of
thrombosis in atrial fibrillation in October, 2010. Recom-
mended doses are 150 mg twice a day for ClCR >3 0m l /
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renal impairment (15-30 ml/min) [17]. This indication
has also recently been approved by the EMA [6].
3.3. Dabigatran for mechanical heart prosthesis
To date, we still do not have any clinical evidence to
evaluate the effect of dabigatran for the prophylaxis of
thrombosis in this clinical setting. No ongoing clinical
trials have been found in http://www.clinicaltrials.gov.
4. Bleeding complications in patients on
dabigatran
Despite the favorable safety profile for dabigatran, sev-
eral concerns exist regarding the best medical care for
patients on dabigatran who suffer from overdosage and
bleeding complications (for example in acute renal fail-
ure), and patients on need of urgent surgery or other
invasive procedures, given the lack of antidote for dabi-
gatran. If possible, the most effective and safe procedure
is discontinuation of the drug, which should be discon-
tinued at least 24 h prior to surgery [18]. However there
is still a lack of clinical evidence about dabigantran
antagonism in an emergent clinical setting. The 2011
ACCF/AHA guidelines suggest the usage of fresh-frozen
plasma, although no clinical trials have been conducted
[19]. This intervention has been questioned from a theo-
retical point of view, given that plasma contains pro-
thrombin. However, it is widely regarded as an efficient
procedure to restore clotting factor depletion, but not a
clotting factor inhibition [20]. The usage of prothrombin
complex may also be theoretically advocated. However,
data from healthy volunteers (n = 12) show that pro-
thrombin complex is unable to normalize APTT, TT
and ECT [21]. Nevertheless, activated prothrombin com-
plex (Feiba
® 50 to100 U/kg) reversed bleeding time, but
not APTT, in a rat model of dabigatran overdose [18],
although data from humans are still lacking. Recombi-
nant factor VII (90 mg/kg) has equally been advocated,
although small human studies in melagatran (not in
dabigatran) have yielded inconsistent findings [18]. To
date, the only proven procedure which has been demon-
strated to rapidly decrease plasma concentration of dabi-
gatran is haemodyalisis. Data from an open-label
pharmacokinetic study in patients with end-stage renal
Table 1 Clinical studies with dabigatran etexilate
Study Phase N Indication Efficacy Safety
Bistro I
[4]
I 289 HR or KR 20.8% VTE in 12.5 mg/12 h vs. 0% 300 mg/12 h 10% bleeding in 300 mg/12 h
Bistro II
[7]
II 1973 HR or KR Lower VTE in 150 mg/12 h, 225 mg/12, 300 mg/24 h,
compared to enoxaparin 40 mg/24 h














III 2596 KR Lower VTE in enoxaparin 30 mg/12 h compared to





MA 8135 HR and KR Similar VTE risk among groups (3 trials) Similar bleeding rate
RE-COVER
[16]
III 2564 DVT/PE Similar efficacy for dabigatran 150 mg/12 h compared to
warfarin
Lower bleeding in the dabigatran group
PETRO
[8]
II 502 AF 2% thromboembolic events when the lowest dose was
used (50 mg/12 h)
Lower bleeding in 50 mg than 150 mg and
300 mg (twice a day)
RE-LY
[10]
III 18113 AF Dose of 150 mg/12 h had lower thromboembolic events
than warfarin. No difference for 110 mg/12 h
Lower major bleeding rate for the dose of 110
mg/12 h, compared to warfarin.
Efficacy and safety headings only describe the conclusions. A deeper description of each study is made in the Text. VTE: Venous thromboembolism. AF: Atrial
fibrillation. HR: Hip replacement. KR: Knee replacement. MA: Meta-analysis. DVT/PE: Deep vein thrombosis/pulmonary embolism.
Table 2 Advantages and disadvantages of dabigatran over VKA
Advantages over VKA Disadvantages over VKA
No need of periodic INR control High prize
Lower interactions Not indicated in renal disease
Favorable safety versus efficacy profile, it may reduce VKA misdosing No antidote and lack of experience in hemorrhage complications
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tion of the drug removed was 62-68% at 2 h, with a par-
allel decrease of APTT and ECT [22]. Yet again, no
clinical data about the role of haemodyalisis in dabiga-
tran bleeding complications or antagonism for emer-
gency surgery are available. The question arises about
how to monitor bleeding complications of dabigatran
when TT and ECT are lacking. Pharmacokinetic data
suggest that, in this case, APTT may be the most useful
test for a qualitative monitoring of dabigatran [18].
5. Conclusion: Advantages and disadvantages of
dabigatran
Dabigatran may suppose a significant change in oral
anticoagulation with a reasonable efficacy and safety
profile, based on the current clinical evidence (Table 1).
This drug may become the oral anticoagulant of choice
in many clinical situations, after an individualized eva-
luation of advantages and disadvantages in every single
patient.
The major advantages of dabigatran over vitamin K
antagonists (VKA) are: the absence of periodic labora-
tory analysis, the low extent of dietary and drug interac-
tions and the favorable safety-efficacy profile, which may
decrease the rate of clinical complications due to an
over abundance of vitamin K inhibitors in selected
patients. The major disadvantages, in addition to the
high prize of the drug, are the lack of evidence in
mechanical heart valves, the dependence of a proper
renal function, and the lack of experience in dabigatran-
associated hemorrhage and reversion for emergent inva-
sive procedures (Table 2).
In conclusion, day-to-day experience in the clinical
arena and high-level clinical evidence will eventually set
the enormous potential importance of this drug in oral
anticoagulation and enhance their safety profile. Clini-
cians should be aware of the coming of this putative
revolutionary change in the field of oral anticoagulation.
Abbreviations
INR: International Normalized Ratio; IC50: half-maximal inhibitory
concentration; Tmax: Time for peak concentration; Cmax; Peak concentration;
ClCR: Creatinine clearance; PT: Prothrombin time; APTT: Activated partial
thromboplastin time; TT: Thrombin time; ECT: Ecarin clotting time; AUC: Area
under curve; EMA: European Medicines Agency; FDA: Food and Drug
Administration; OR: Odds ratio; CI: Confidence interval; DTB2: 11-
dehydrothromboxane B2; VTE: Venous thromboembolism; AF: Atrial
fibrillation; HR: Hip replacement; KR: Knee replacement; MA: Meta-analysis;
DVT/PE: Deep vein thrombosis/pulmonary embolism; VKA: Vitamin K
antagonists.
Acknowledgements and disclosures
Our lab receives support from FISS (Health Research Fund, PI080920) and
Red Tematica de Investigacion Cardiovascular RECAVA (RD06/0014/1007),
both from the Instituto de Salud Carlos III (ISCIII). These institutions had no
role in collection, management, analysis, interpretation of the data,
preparation, review, or approval of the present work. Santiago Redondo has
given conferences and received honoraria from Gilead and Merck Sharp &
Dohme.
Author details
1Service of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain.
2Department of Pharmacology, School of Medicine, Universidad
Complutense de Madrid, Spain.
Authors’ contributions
SR and TT developed the original idea of the manuscript and undertook the
first bibliographic research. MR, JN-D, MPM and AB participated in the final
draft of the work. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 November 2011 Accepted: 21 December 2011
Published: 21 December 2011
References
1. Wienen W, Stassen JM, Priepke H: In-vitro profile and ex-vivo
anticoagulant activity of the direct thrombin inhibitor dabigatran and its
orally active prodrug, dabigatran etexilate. Thromb Haemost 2007,
98:155-162.
2. Garcia D, Libby E, Crowther MA: The new oral anticoagulants. Blood 2010,
115:15-20.
3. Stangier J: Clinical pharmacokinetics and pharmacodynamics of the oral
direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetis
2008, 47:285-295.
4. Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G,
Hermansson K, Kohlbrenner V: Dose escalating safety study of a new oral
direct thrombin inhibitor, dabigatran etexilate, in patients undergoing
total hip replacement: BISTRO I. J Thromb Haemost 2004, 2:1573-1580.
5. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W: The pharmacokinetics,
pharmacodynamics and tolerability of dabigatran etexilate, a new oral
direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharm 2007,
64:292-303.
6. European Medicines Agency. Dabigatran label [http://www.ema.europa.
eu].
7. Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML,
Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P, BISTRO II Study Group: A
new oral direct thrombin inhibitor, dabigatran etexilate, compared with
enoxaparin for prevention of thromboembolic events following total hip
or knee replacement: the BISTRO II randomized trial. J Thromb Haemost
2005, 3:103-111.
8. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-
Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with
or without concomitant aspirin compared with warfarin alone in
patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol
2007, 100:1419-1426.
9. Boerhinger-Ingelheim. Dabigatran Advisory Committee Briefing Document
[http://www.fda.org].
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D,
Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY
Steering Committee and Investigators: Dabigatran versus warfarin in
patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
11. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nyström P,
Bylock A, ESTEEM Investigators, et al: Oral ximelagatran for secondary
prophylaxis after myocardial infarction: the ESTEEM randomised
controlled trial. Lancet 2003, 362:789-797.
12. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP,
Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR, RE-
MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous
enoxaparin for the prevention of venous thromboembolism after total
knee replacement: the RE-MODEL randomized trial. J Thromb Haemost
2007, 5:2178-2185.
13. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP,
Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR, RE-NOVATE Study
Group, et al: Dabigatran etexilate versus enoxaparin for prevention of
Redondo et al. Journal of Hematology & Oncology 2011, 4:53
http://www.jhoonline.org/content/4/1/53
Page 6 of 7venous thromboembolism after total hip replacement: a randomised,
double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
14. Ginsberg JS, Davidson BL, Comp PC, RE-MOBILIZE Writing Committee, RE-
MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC,
Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE,
Clements ML, Hantel S, Schnee JM, Caprini JA, et al: Oral thrombin
inhibitor dabigatran etexilate vs North American enoxaparin regimen for
prevention of venous thromboembolism after knee arthroplasty surgery.
J Arthroplasty 2009, 24:1-9.
15. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW,
Clemens A, Hantel S, Schnee JM, Eriksson BI, RE-MOBILIZE, RE-NOVATE
Steering Committees: Dabigatran versus enoxaparin for prevention of
venous thromboembolism after hip or knee arthroplasty: A pooled
analysis of three trials. J Thromb Haemost 2010, 126:175-182.
16. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H,
Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group: Dabigatran
versus Warfarin in the Treatment of Acute Venous Thromboembolism.
New Engl J Med 2009, 361:2342-2352.
17. Food and Drug Administration. Dabigatran label [http://www.fda.org].
18. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M,
Clemens A: Dabigatran etexilate–a novel, reversible, oral direct thrombin
inhibitor: interpretation of coagulation assays and reversal of
anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
19. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM,
January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM: 2011
ACCF/AHA/HRS focused update on the management of patients with
atrial fibrillation (update on dabigatran): a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on practice guidelines. J Am Coll Cardiol 2011, 57:1330-1337.
20. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW: Dabigatran:
Review of Pharmacology and Management of Bleeding Complications of
This Novel Oral Anticoagulant. J Med Toxicol 2011.
21. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M:
Reversal of rivaroxaban and dabigatran by prothrombin complex
concentrate: a randomized, placebo-controlled, crossover study in
healthy subjects. Circulation 2011, 124:1573-9.
22. Stangier J, Rathgen K, Stähle H, Mazur D: Influence of renal impairment on
the pharmacokinetics and pharmacodynamics of oral dabigatran
etexilate: an open-label, parallel-group, single-centre study. Clin
Pharmacokinet 2010, 49:259-68.
doi:10.1186/1756-8722-4-53
Cite this article as: Redondo et al.: Pharmacological basis and clinical
evidence of dabigatran therapy. Journal of Hematology & Oncology 2011
4:53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Redondo et al. Journal of Hematology & Oncology 2011, 4:53
http://www.jhoonline.org/content/4/1/53
Page 7 of 7